Evidence map›Paper›PMID 35133989›Full record

Trial reportJCI insight2022

A 4-week high-AGE diet does not impair glucose metabolism and vascular function in obese individuals.

Armand Ma Linkens, Alfons Jhm Houben, Petra M Niessen, Nicole Eg Wijckmans, Erica Ec de Goei, Mathias Dg Van den Eynde, Jean Ljm Scheijen, Marjo Ph van den Waarenburg, Andrea Mari, Tos Tjm Berendschot and 7 more

Registry-linked trialOpen access · goldAbstract readRandomized Controlled Trial
In one paragraph

Trial report in JCI insight, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03866343 (Restriction of Dietary AGEs to Prevent Diabetes in Overweight Individuals), which is not on this map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
5.2field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03866343 nacompletednot on this map

Restriction of Dietary AGEs to Prevent Diabetes in Overweight Individuals: a Randomized Controlled Trial

TypeinterventionalSponsorMaastricht University Medical CenterRan2018 to 2021Enrolled82ConditionsAdvanced Glycation Endproducts, AGEs, Diet, Insulin Sensitivity/ResistanceArmsDiet low or high in advanced glycation endproducts
3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 27 citations in OpenAlex.

  1. Trial
  2. Dietary Advanced Glycation End Products and Cardiovascular-Kidney-Metabolic Complications.Clinical journal of the American Society of Nephrology : CJASN · 2026
    Review
  3. Review
  4. Article
  5. Article
  6. Review
  7. Review
  8. Review
  9. Dietary NWorld journal of diabetes · 2022
    Article
  10. Review
  11. Review
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 3 institutions in 3 countries.

Armand Ma LinkensDepartment of Internal Medicine, Maastricht University Medical Center, Maastricht, Netherlands.
Alfons Jhm HoubenDepartment of Internal Medicine, Maastricht University Medical Center, Maastricht, Netherlands.
Petra M NiessenDepartment of Internal Medicine, Maastricht University Medical Center, Maastricht, Netherlands.
Nicole Eg WijckmansDepartment of Epidemiology, and.
Erica Ec de GoeiDepartment of Epidemiology, and.
Mathias Dg Van den EyndeDepartment of Internal Medicine, Maastricht University Medical Center, Maastricht, Netherlands.
Jean Ljm ScheijenDepartment of Internal Medicine, Maastricht University Medical Center, Maastricht, Netherlands.
Marjo Ph van den WaarenburgDepartment of Internal Medicine, Maastricht University Medical Center, Maastricht, Netherlands.
Andrea MariInstitute of Neuroscience, National Research Council, Padua, Italy.
Tos Tjm BerendschotUniversity Eye Clinic Maastricht, Maastricht University Medical Center, Maastricht, Netherlands.
Lukas StreeseDivision of Sports and Exercise Medicine, Department of Sport, Exercise and Health, University of Basel, Basel, Switzerland.
Henner HanssenDivision of Sports and Exercise Medicine, Department of Sport, Exercise and Health, University of Basel, Basel, Switzerland.
Martien Cjm van DongenDepartment of Epidemiology, and.
Christel Cjaw van GoolDepartment of Epidemiology, and.
Coen DA StehouwerDepartment of Internal Medicine, Maastricht University Medical Center, Maastricht, Netherlands.
Simone Jmp EussenCARIM School for Cardiovascular Diseases.
Casper G SchalkwijkDepartment of Internal Medicine, Maastricht University Medical Center, Maastricht, Netherlands.
Maastricht University · NLUniversity of Basel · CHNational Research Council · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUNDAccumulation of advanced glycation endproducts (AGEs) may contribute to the pathophysiology of type 2 diabetes and its vascular complications. AGEs are widely present in food, but whether restricting AGE intake improves risk factors for type 2 diabetes and vascular dysfunction is controversial.METHODSAbdominally obese but otherwise healthy individuals were randomly assigned to a specifically designed 4-week diet low or high in AGEs in a double-blind, parallel design. Insulin sensitivity, secretion, and clearance were assessed by a combined hyperinsulinemic-euglycemic and hyperglycemic clamp. Micro- and macrovascular function, inflammation, and lipid profiles were assessed by state-of-the-art in vivo measurements and biomarkers. Specific urinary and plasma AGEs Nε-(carboxymethyl)lysine (CML), Nε-(1-carboxyethyl)lysine (CEL), and Nδ-(5-hydro-5-methyl-4-imidazolon-2-yl)-ornithine (MG-H1) were assessed by mass spectrometry.RESULTSIn 73 individuals (22 males, mean ± SD age and BMI 52 ± 14 years, 30.6 ± 4.0 kg/m2), intake of CML, CEL, and MG-H1 differed 2.7-, 5.3-, and 3.7-fold between the low- and high-AGE diets, leading to corresponding changes of these AGEs in urine and plasma. Despite this, there was no difference in insulin sensitivity, secretion, or clearance; micro- and macrovascular function; overall inflammation; or lipid profile between the low and high dietary AGE groups (for all treatment effects, P > 0.05).CONCLUSIONThis comprehensive RCT demonstrates very limited biological consequences of a 4-week diet low or high in AGEs in abdominally obese individuals.TRIAL REGISTRATIONClinicaltrials.gov, NCT03866343; trialregister.nl, NTR7594.FUNDINGDiabetesfonds and ZonMw.

Indexed as

Diabetes Mellitus, Type 2Insulin ResistanceDietGlucoseGlycation End Products, AdvancedHumansInflammationLipidsLysineMaleObesityGlucoseGlycation End Products, AdvancedLipidsLysineClinical TrialsGlucose metabolismMicrocirculationVascular Biology

Identifiers

PMID35133989
PMCPMC8986074
OpenAlexW4210945235

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.